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Amp   Ampicillin 
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Protein kapsid p24 memainkan peranan yang penting dalam peringkat awal dan 
akhir replikasi HIV. Justeru, kapsid HIV-1 dianggap sebagai sasaran penting dalam 
pembangunan ubat terapi baharu untuk merawat HIV/AIDS. Perencat peptida seperti 
CAP-1, CAI dan NYAD-1 mampu menyekat fungsi kapsid HIV-1 dalam sel yang 
dijangkiti HIV. Walau bagaimanapun, sifat peptida yang kurang stabil dalam darah, 
menyebabkan ia cepat dilupuskan dari sistem malah kurang spesifik terhadap sasaran. 
Sebaliknya, antibodi monoklon (MAb) bersifat lebih stabil dan spesifik. Antibodi 
monoklon telahpun digunapakai sebagai modaliti terapi untuk merawat pelbagai 
penyakit termasuk kanser dan jangkitan virus. Namun, keberkesanan antibodi masih 
dipersoal kerana tidak dapat menembusi sel untuk menyasar sasaran dalam sel seperti 
kapsid HIV. Dengan ini, antibodi monoklon anti-p24 telah dihasilkan secara 
kejuruteraan kimia dengan peptida penembus sel yang dapat mensasarkan sasaran p24 
dalam sel (anti-p24-TransMAbs). Dalam kajian ini, antibodi anti-p24 telah dicantum 
dengan lapan jenis peptida penembus sel secara pengoksidaan periodate. Ujian p24 
ELISA dan microskopi berpendafluor kemudiannya digunapakai untuk menilai tahap 
penembusan dalam sel. Antibodi anti-p24 yang digabungkan dengan MTS mempunyai 
tahap penembusan sel yang paling berkesan. Penembusan sel ini adalah bergantung 
kepada kepekatan peptida dan hasil maksimum diperoleh selepas 24 jam rawatan. 
Rawatan setinggi 10µg/mL anti-p24-TransMAbs tidak menunjukkan sebarang kesan 
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toksik pada sel. Kajian mekanikal menunjukkan bahawa rawatan anti-p24-TransMAbs 
dalam monosit adalah bergantung kepada suhu and tenaga serta dikawal separa oleh 
endositosis clathrin dan caveolae. Sebaliknya, rawatan anti-p24-TransMAbs dalam 
limfosit T tidak bergantung kepada endositosis. Berdasarkan ujian sel MAGI untuk 
menyukat tahap jangkitan HIV-1, 10µg/mL anti-p24-TransMAbs berjaya mengurangkan 
tahap jangkitan HIV-1 sebanyak 66% dalam sel Jurkat-T dan 94% dalam sel H9, namun 
aktiviti lebih rendah dilihat dalam sel THP-1 (38%) dan sel U937 (27%). Tambahan pula, 
aktiviti virus dapat dikawal oleh antibodi ini dalam PBMCs (48%) dan sel CD4
+
-T 
(60%). Sebagai kesimpulan, anti-p24-TransMAbs berpotensi sebagai terapi HIV/AIDS 
yang baharu. Strategi yang sama juga boleh digunapakai untuk menyasarkan protein 
HIV lain seperti Nef, Vif dan Vpr. Untuk meningkatkan aktiviti antibodi ini, kami 
memilih antibodi monoklon yang lebih reaktif dengan teknologi phage-display. Antibodi 
dalam format scFv ini sedang dihasilkan dan digabung dengan MTS secara molekular 















The capsid protein plays seminal roles in both early and late stages of the HIV 
replication cycle. Hence, HIV-1 capsid protein is considered an important target for 
developing novel drugs to treat HIV/AIDS. Capsid molecule (CA)-targeting peptide 
inhibitors (CAP-1, CAI and NYAD-1) have been reported to disrupt the capsid protein 
functions in HIV-infected cells. However, the peptides are less stable in the blood, thus 
resulting in rapid clearance from the system and they can exhibit off-target activities. 
Monoclonal antibodies (MAbs) on the other hand, are stable and highly specific 
molecule, which have been successfully used as therapeutic modalities to treat various 
types of cancer and viral infections. Nonetheless, MAbs cannot penetrate into the cell 
and interact with intracellular target such as HIV-1 CA. To this end, anti-p24 MAbs 
were chemically engineered with cell-penetrating peptides (CPPs) to generate cell-
penetrable (anti-p24-TransMAbs). In this study, anti-p24 MAbs were conjugated with 8 
different CPPs through periodate oxidation. The cell penetration of anti-p24-TransMAbs 
was then examined by p24 ELISA and fluorescence microscopy. Anti-p24 MAbs 
conjugated with MTS (membrane-transduction sequence) resulted in most efficient 
penetration into the cells. The internalization of anti-p24-TransMAbs was concentration-
dependent and maximum at 24 hours incubation. No toxicity was observed when the 
cells were treated with up to 10µg/mL anti-p24-TransMAbs. Mechanistic studies 
showed that the transportation of anti-p24-TransMAbs in promonocytic cell lines was 
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temperature- and energy-dependent, and partially mediated by clathrin and caveolae-
dependent endocytic pathways. On the other hand, the transportation of anti-p24-
TransMAbs in T-lymphocytic cell lines did not depend on endocytosis and resulted from 
CPP-mediated membrane perturbation. Using MAGI (multinuclear-activation 
galactosidase indicator) cell assay, the 10µg/mL anti-p24-TransMAbs successfully 
reduced the HIV-1 infectivity in Jurkat-T (66%) and H9 (94%) lymphocytic cell lines 
while lower inhibition was seen in infected THP-1 (38%) and U937 (27%) 
promonocytic cell lines. More promisingly, pronounced antiviral effects were seen in 
PHA-stimulated infected human PBMCs (48%), and infected primary human CD4
+
-T-
cells (60%). We conclude that anti-p24-TranMAbs targeting HIV-1 CA can be 
developed into a novel HIV/AIDS therapy. Similar strategy can also be potentially 
applied on targeting other intracellular HIV-1 protein such as Nef, Vif and Vpr. To 
further enhance the antiviral activity of antibody, we are currently selecting the 
monoclonal antibody against the capsid protein by phage-display technology. The 
antibody in scFv format are being generated and molecularly conjugated with MTS to 









1.1. HIV/AIDS pathogenesis 
1.1.1. Acquired Immunodeficiency Syndrome (AIDS) 
 AIDS is today’s global life-threatening concern. Since its first identification in 
United States in 1981 (CDC Morbidity & Mortality Weekly Report, 1981), an increased 
number of infections and deaths attributed to AIDS have been reported. In 1983, Human 
Immunodeficiency Virus (HIV) was identified as the causative agent for AIDS (BarreÂ-
Sinoussi et al., 1983). According to Joint United Nations Programme on HIV/AIDS 
(UNAIDS), approximately 35 million people worldwide were living with HIV/AIDS in 
2013, and 19 million of them do not know that they have the virus. In 2013 alone, 1.5 
million people have died of AIDS-related causes. Sub-Saharan Africa remains the region 
with highest number of reported cases in 2013 (24.7 million out of 35 million that 
accounts for 70.6% of global statistics) and more than 70% of all people of the country 
are living with HIV (UNAIDS Gap Report 2014). There are also a strikingly high 
number of AIDS-related cases in Malaysia. By the end of 2013, Malaysia had a 
cumulative number of 101,672 HIV-related cases, 20,235 reported AIDS and 16,340 
AIDS-related deaths since the first occurrence in 1986 (Global AIDS Response Progress 
Report 2014).  
 In infected patients, the HIV presents either as free virus particles or lie within 
infected immune cells in biological fluids. HIV infects vital cells in the human immune 
system such as CD4
+
-T-lymphocytes, monocytes/macrophages, and dendritic cells 
(DCs). Notably, a HIV-positive individual may not necessarily be AIDS-positive due to 
the clinical latency period that can last up to ten years or longer. During this period, the 
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virus wears down the immune system, rendering the body susceptible to ‘opportunistic 
infections’ and other medical complications (Figure 1.1). The latter usually happens 
when the total CD4
+
-T-cells or "T-helper" cells, which are important component of the 
immune system, is less than 200 cells per cubic milliliter of blood (200 cells/mm
3
). 
Healthy individuals usually have 500 - 1,500 cells/mm
3
. The late stage of AIDS is often 
complicated by cancer and other opportunistic infections (Figure 1.2). These 













Figure 1.1. Levels of CD4
+
-T-lymphocytes and HIV RNA copies throughout AIDS 
progression. The graph shows the general relationship of CD4
+
-T-lymphocytes 
numbers (blue line) and viral load (red line) over the course of HIV infection. The 
CD4
+
-T-lymphocytes number drops during the first 6-week of primary infection while 
the HIV replicates and spreads to multiple organs. The HIV number then significantly 
drops after the successful infection and gradually increases during the clinical latency 
while the CD4
+
-T-lymphocytes drop every year. At the late stage of infection (CD4
+
-T-
lymphocytes number is less than 200 cells/mm
3
), the immune system is compromised 
and attacked by multiple ‘opportunistic’ diseases. Due to the non-functional immune 












Figure 1.2. Occurrence of opportunistic infections and cancers over the course of 
HIV infection. During the primary infection, common symptoms of viral infections are 
seen such as fever and rashes. As the CD4
+
-T-cell count drops due to the HIV infection 
that compromises the immune sytem, the host becomes infected by more deadly 
infections (tuberculosis, pneumonia, candidiasis, etc.) and cancer diseases (lymphoma, 
sarcoma, etc.).  
 













1.1.2. Human Immunodeficiency Virus (HIV) 
HIV is an enveloped virus of 100-120nm containing two copies of approximately 
9kb genomic RNA. HIV originates from lentiviridae subfamily of the retroviridae 
family, and there are two subtypes: HIV-1 and HIV-2. HIV-1 is more virulent and 
infective, thus contributing largely to the global infections whereas HIV-2 infection is 
only confined to West Africa (CDC Morbidity & Mortality Weekly Report, 2011). Upon 
viral entry into the target cells, the genomic RNA is reverse-transcribed into 
complimentary DNA (9.8kb) and gets integrated into the host genome. The virus then 
becomes latent and can reside in the host cells for a long period of time. HIV-1 is 
morphologically spherical and it encodes a total of three structural proteins, two 
envelope proteins, three enzymes, and six accessory proteins (Turner and Summers, 
1999).    
 The viral genomic material is surrounded by an outer coat or viral envelope 
(Figure 1.3), composing of two layers of host cell-derived phospholipids during the 
budding of viral particles. The envelope also consists of cap-like protruded proteins 
made up of three molecules of knob-like glycoprotein 120 (gp120), and a stem 
consisting of three spike-like molecules known as glycoprotein 41 (gp41) that anchor the 
structure in the viral envelope. Both of these envelope-associated protein are cleaved by 
protease from glycoprotein 160 (gp160) coded by env gene (Figure 1.4). These protein 
structures play important roles in establishing the HIV infection during the attachment 





Figure 1.3. Structure of immature and mature forms of HIV-1. The mature HIV-1 
contains a bullet-shaped core encapsulating RNA genome and viral enzymes whereas 
the immature HIV-1 has a ‘hollow’ centre due to the unprocessed gag-pol genes.  
 






Figure 1.4. The HIV genome, transcripts, and proteins. (a) HIV transcripts consist of 
10kb viral genome containing open reading frames for 16 proteins that are synthesized 
from at least 10 transcripts. (b) gag, pol and env precursors are processed by the viral 
proteases to form HIV proteins essential and accessory for AIDS progression. 
 
Source: Peterlin and Trono, 2003. 
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Within the viral envelope, a layer of matrix protein composing of viral protein, 
MA or p17 helps to maintain the integrity of the virion particle. At the center of virus, 
there is a bullet-shaped core surrounded by a conical capsid made up of approximately 
2,000 copies of the viral protein, CA or p24 (Luciw, 1996).  The viral core contains two 
single strands of RNAs that encode the HIV-1 genome. These RNAs are tightly bound to 
the nucleocapsid proteins that are composed of NC or p7. The core also contains a few 
other viral enzymes such as reverse transcriptase, ribonuclease, proteases, and integrase 
that play important roles in the replication cycle (Freed, 2001). Three of the structural 
proteins (MA, CA and NC) are encoded by gag gene whereas pol gene encodes for the 
viral enzymes. 
Other than env, gag and pol genes, which are indispensable for HIV-1 replication, 
the RNA genome also contains other regulatory genes such as nef, tat, rev, vpu, vpr, vif, 
and sometimes tev (fusion of tat, env and rev) (Table 1.1). Although they are not 
compulsorily required for replication, a majority of them have distinct functions that 
contribute to the enhanced viral infectivity and disease progression (Bour and Strebel, 
2000; Steffens and Hope, 2001; Anderson and Hope, 2003; Seelamgari et.al., 2004). 
These regulatory genes can be separated into three categories – positive regulatory genes, 
negative regulatory genes and unspecified regulatory genes in which the exact functions 
are still largely unknown. The positive regulatory genes enhance and express regulatory 
proteins that promote formation of viral particles and viral infectivity while the negative 





Table 1.1. Summary of functions of genes encoded in HIV-1 genome. gag, env and 
pol are precursors that produce essential proteins for HIV-1 replication. Other accessory 
genes indirectly regulate HIV-1 infectivity and AIDS progression. 
 
Viral gene Regulation Activities towards HIV/AIDS pathogenesis 
   
env Structural  Encodes the outer protein coat gp160 which then processed by a 
protease into gp120 and gp41. 
 
gag Structural Encodes internal proteins such as p17, p24, p7, and p9. 
 
pol Structural Encodes the HIV core including p7, p9, RNA genome, reverse 
transcriptase, ribonuclease, integrase, and protease. 
 
tat Positive  A trans-activator of transcription which accelerates viral protein 
production of proviral genome several 1000-folds. Also up-
regulates rev, nef, and itself. 
 
nef Positive  Affects cellular genes by down-modulating CD4/CD8 and MHC-I/II 




Increased level of rev enhances RNA expression and greater amount 
expression of Env proteins. Also down-regulates tat and itself and 
activates transport of viral mRNA from nucleus into cytoplasm. 
 
vpr Positive  A weak transcriptional activator that moderates stimulation of LTR, 
thus enhancing induction of HIV. 
 
vpu Negative  When vpu is defective, HIV replicates more quickly. Also suppresses 
CD4/Env interactions in the cell. 
 
vif Positive  Increases the infectivity of HIV and cell-to-cell (human-to-human) 
transmission. However, vif-deficient HIV still infects in vitro, but 




A fusion protein resulting from a frameshift reading the mRNA--
mixes up tat/ env/ rev--and apparently has full functional capacity 
of tat and rev. 
 
MHC – major histocompatibility; LTR – long tandem repeat. 








1.1.3.  Disease control of AIDS 
In the past ten years, various anti-HIV therapies targeting multiple components 
of the virus have been developed and some are currently under clinical trials (Maartens 
et.al., 2014). However, the ability of HIV to develop resistance towards currently 
available antiviral agents has rendered the drug development challenging. Some of 
antiviral drugs approved by the Food and Drug Administration (FDA) are summarized 
in Table 1.2. These therapeutic agents were designed based on the understanding of 
establishment of HIV-1 infection, which involves multiple steps in the replication cycle. 
The protein-protein interaction between the virus and the host cells are the keys to 
unlock new therapeutic avenues (Thompson et.al., 2012; Wilen et.al., 2012). The HIV-1 












Table 1.2. List of FDA-approved anti-HIV drugs. Different classes of anti-HIV drugs 
were designed to target multiple components of HIV in the replication cycle. 
 
Drug Class Generic Name Brand Name  FDA Approval Date 
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
NNRTIs bind to and alter 
reverse transcriptase, an 
enzyme HIV needs to make 
copies of itself 
Delavirdine (DLV) Rescriptor  April 4, 1997 
Efavirenz (EFV) Sustiva  Sep 17, 1998 
Etravirine (ETR) Intelence  Jan 18, 2008 
Nevirapine (NVP) Viramune  June 21, 1996 
Rilpivirine (RPV) Edurant  May 20, 2011 
 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
NRTIs block reverse 
transcriptase, an enzyme 
HIV needs to make copies 
of itself 
Abacavir (ABC) Ziagen  Dec 17, 1998 
Didanosine (ddl) Videx 
Videx EC 
 Oct 9, 1991 
Oct 31, 2000 
Emtricitabine (FTC) Emtriva  July 2, 2003 
Lamivudine (3TC) Epivir  Nov 17, 1995 
Stavudine (d4T) Zerit  June 24, 1994 
Tenofovir DF (TDF) Viread  Oct 26, 2001 
Zidovudine (ZDV) Retrovir  March 19, 1987 
 
Protease Inhibitors (PIs) 
PIs block HIV protease, an 
enzyme HIV needs to make 
copies of itself 
Atazanavir (ATV) Reyataz  June 20, 2003 
Darunavir (DRV) Prezista  June 23, 2006 
Fosamprenavir (FPV) Lexiva  Oct 20, 2003 
Indinavir (IDV) Crixivan  March 13, 1996 
Nelfinavir (NFV) Viracept  March 14, 1997 
Ritonavir (RTV) Norvir  March1, 1996 
Saquinavir (SQV) Invirase  Dec 6, 1995 
Tipranavir (TPV) Aptivus  June 20, 2005 
 
Fusion Inhibitors 
Fusion inhibitors block HIV 
from entering CD4 cells of 
the immune system. 
 
Enfuvirtide (T-20) Fuzeon  March 13, 2003 
CCR5 Antagonists 
CCR5 entry inhibitors block 
CCR5, a protein on the CD4 
cells that HIV needs to enter 
the cells 
 
Maraviroc (MVC) Selzentry  Aug 6, 2007 
Integrase Inhibitors 
Integrase inhibitors block 
HIV integrase, an enzyme 
HIV needs to make copies 
of itself 
 
Raltegravir (RAL) Isentress  Oct 12, 2007 
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tablets contain two or more 
anti-HIV medications from 
one or more drug classes. 
Abacavir, Lamivudine Epzicom  Aug 2, 2004 
Abacavir, Lamivudine, 
Zidovudine 
Trizivir  Nov 14, 2000 
Efavirenz, Emtricitabine, 
Tenofovir DF 
Atripla  July 12, 2006 
Elvitegravir, Cobicistat, 
Emtricitabine, Tenofovir DF 
Stribild  Aug 27, 2012 
Emtricitabine, Rilpivirine, 
Tenofovir DF 
Complera  Aug 10, 2011 
Emtricitabine, Tenofovir DF Truveda  Aug 2, 2004 
Lamivudine, Zidovudine Combivir  Sep 27, 1997 
Lopinavir, Ritonavir Kaletra  Sep 15, 2000 
 
 
HIV and its treatment – FDA-approved anti-HIV medications. U.S. Department of health and human 
services guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Reviewed 
on Aug 2012.  
 







Figure 1.5. HIV-1 replication cycle and potential antiviral targets. A free virus 
interacts with a cell that contains essential receptors (CD4 and CXCR4 or CCR5) for 
establishment of infection. This interaction can be blocked by attachment and fusion 
inhibitors. Viral RNA is uncoated, reverse-transcribed, and integrated into host genome 
for viral protein production. Reverse transcription can be blocked by reverse 
transcriptase inhibitors whereas the DNA integration can be inhibited by integrase 
inhibitors. RNA and viral proteins assembles at the membrane for synthesis of a new 
viral particle. Upon the release and maturation of virus, protease acts on the Gag and 
Gag-Pol precursors to form an infectious particle. This step can be effectively blocked 
by protease inhibitors.  
 
Adapted and modified from De Clercq, 2007. 
14 
  
Most anti-HIV therapies comprise single or dual agents, which target surface 
protein (gp41 and gp120) and viral enzymes (reverse transcriptase, integrase and 
protease) (Peters and Conway, 2011). The strikingly rapid resistance of HIV-1 remains a 
huge problem until highly active antiretroviral therapies (HAART) was introduced in 
1995 (Hammer et.al., 1996, 1997). HAART consists of drug cocktails (combination of 
three to four different classes of drugs) that act on multiple targets of HIV-1 in order to 
interrupt the viral life cycle at different steps. Often, the drugs used in HAART are of 
reverse transcriptase inhibitors, protease inhibitors, and fusion inhibitors classes. This 
therapy has successfully controlled the infection by reducing total viral load and 
significantly delaying disease progression (Walensky et.al., 2006; Arts and Hazuda, 
2012) while dramatically diminishing the mutation rate of HIV-1 strains (Piacenti, 2006). 
The clinical profile that exhibits increased survival rates after introduction of HARRT is 
depicted in Figure 1.6. However, the emergence of HAART-escaped HIV-1 mutant 
strains remains a major concern, and other relatively effective alternatives are still under 









Figure 1.6. Increased survival rates of AIDS by HAART. The development of highly 
active antiretroviral therapy (HAART) has been the driving force behind a revolution in 
the treatment of HIV/AIDS. Since the introduction of HAART in 1996, the reported new 




















1.1.4. Drawbacks of current therapies 
Albeit the rate of disease progression being successfully suppressed by the 
HAART intervention (Figure 1.6), the drug resistance remains unresolved. Following a 
long exposure of drugs, the therapy will eventually become inefficient due to the 
acquired resistance of so-called ‘escaped mutants’. The virus will strike back and 
progressively destroys the immune system. Furthermore, HAART may not be efficient 
to all AIDS patients due to poor compliance. The patients need to adhere strictly to a 
dosage schedule as HAART possesses a complicated regimen requiring patients to take 
a series of pills at multiple times of the day (Piacenti, 2006; Peters and Conway, 2011; 
Arts and Hazuda, 2012), which significantly affect their life qualities. Moreover, the cost 
of these multiple antiviral drugs is high (Schackman et.al., 2006).  
HAART is also notorious of its short- and long-term side effects (Table 1.3). 
Patients under long-term treatment may also develop several clinical presentations such 
as lipodystrophy, hyperglycemia, diabetes, liver toxicity, and debilitating inflammatory 
syndrome (Jones and Núñez, 2012). These severe side effects may force the patients to 
skip the medication, rendering the therapy inefficient, and more crucially, promotes drug 
resistance. Due to these adverse effects, many cases have reported that the patients 
discontinued the HAART within the first year of medication (Robison et.al., 2008; 
Cicconi et.al., 2010; Woldemedhin and Wabe, 2012). With advents of these drawbacks 
and failure of vaccination, there is a pressing need to develop alternative therapies for 





Table 1.3. Side effects of HAART. Adverse effects of various drug types used in 
HAART. 





Nausea, diarrhea, headache, hypersensitivity syndrome, lactic acidosis, 
hepatic steatosis, pancreatitis, lipodystrophy, peripheral neuropathy, 





Nausea, diarrhea, headache, dizziness, Stevens-Johnson syndrome, 
toxic epidermal necrolysis, hyperlipidemia, hepatitis, and elevations in 
liver function tests. 
 
Protease Inhibitors (PIs) Nausea, diarrhea, headache, dyslipidemia, hyperglycemia, insulin 
resistance, hyperbilirubinemia, nephrolithiasis, lipodystrophy, and 
elevations in liver function tests. 
 





Nausea, diarrhea, headache, hepatitis, joint or muscle pain, and 
elevations in liver function tests. 
 
Integrase Inhibitors Nausea, diarrhea, headache, muscle pain, and elevations in amylase and 
liver function tests. 
 
Pharmacokinetic Enhancers  Nausea, diarrhea, headache, increased serum creatinine, and proteinuria 
 




















1.2. Capsid protein in HIV-1 infectivity  
1.2.1. Biological function of capsid protein 
 Assembly of viral particles and their maturation into infectious particles after 
viral budding are indispensable steps in HIV-1 replication cycle (Figure 1.5). Capsid 
molecule (CA) or p24 is known to play important roles in early (pre-integration) and late 
(post-integration) events of the replication cycle (Adamson and Freed, 2007; Briant 
et.al., 2011; Sundquist and Kräusslich, 2012). Upon cell entry, the capsid protein 
releases the RNAs and viral enzymes into the cell cytoplasm. Once the reverse-
transcribed DNA is integrated into the host genome, viral proteins are produced and 
repackaged by the capsid protein for new infections.   
CA is initially synthesized as a domain within a 55kDa Gag precursor 
polyprotein. Gag (p55) sometimes interacts with another large viral protein, Gag-Pol 
(160kDa) in the viral assembly. Approximately 2000-4000 copies of intact Gag 
polyprotein assemble at the cell membrane and bud to produce immature virus particles 
(Ganser-Pornillos et.al., 2008, 2012) (Figure 1.7). The intact Gag attaches to the inner 
cell membrane via the myristoylated N-terminus of matrix molecule (MA), one of the 
cleavage products of Gag. A proteolytic cleavage by viral protease then takes place and 
Gag is subsequently broken into CA, MA, nucleocapsid molecule (NC), and p6 
molecules. Additionally, splicing of several spacer peptides (SP) that stabilizes CA 
hexamers occurs sequentially to complete the Gag proteolytic process. For instance, 
spacer peptide-1 (SP1) stabilizes CA and NC, whereas SP2 stabilizes NC and p6 
(Figure 1.7). In Gag-Pol protein, the Pol domain is cleaved into viral enzymes such as 
reverse transcriptase, protease, and integrase proteins (Meng et.al., 2012).   
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CA develops into a cone-shaped capsid that encases the RNA genome and 
several viral enzymes, which then develops into mature infectious particles. Throughout 
the HIV-1 replication, capsid protein plays an important role in virus assembly and 
maturation. Without the proper assembly of capsid, mature virions cannot be formed 
hence affecting HIV-1 replication and infectivity. It has been reported that mutated CA 
in which the capsid stability was affected, significantly attenuated the HIV-1 replication 
(Neira, 2009; Blair et.al., 2010). In recent years, the essential role of capsid protein in 
HIV-1 replication cycle has drawn considerable attention of researchers to study its 

































Figure 1.7. Assembly of Gag on cell membrane and its proteolytic cleavage. After 
protein synthesis, HIV-1 Gag assembles on the plasma membrane to form immature 
particles. The Gag precursors are cleaved by viral proteases into four structural proteins 
(MA – matrix molecule, CA – capsid molecule, NC – nucleocapsid molecule, and p6 - 
p6 molecule) upon maturation. 
 













1.2.2. Structure of capsid protein 
In 2007, the three-dimensional structure of HIV-1 capsid was revealed by cryo-
electron microscopy (cryoEM) (Ganser-Pornillos et.al., 2007), and the complete 
structure of capsid in both immature and mature forms were recently studied (Bharat 
et.al., 2012; Zhao et.al., 2013). CA forms a tube-like structure in vitro and assembles 
into spherical structure (Figure 1.8). This protein comprises two domains and has 
distinct roles in stabilizing the viral capsid architecture. They are N-terminal domain 
(NTD), residues 1-146 that forms hexamers and C-terminal domain (CTD), residues 
147-231, which is dimeric in solution (Ganser-Pornillos et.al., 2007).  
Each CA hexamer is composed of an inner ring of six NTDs and an outer ring of 
CTD (Figure 1.9c). Both of these independently folded domains are separated by a 
flexible linker but interacting closely with each other to form a compact structure 
(Figure 1.9d). Both domains predominantly compose of α-helical secondary structures. 
The arrowhead-like NTD contains seven α-helices (numbered 1–7) and an amino-
terminal β-hairpin, while the globule-like CTD is made up of a single-turn 310-helix and 












Figure 1.8. Characterization of HIV-1 CA hexametric lattice. Negative stain electron 
micrograph that shows (A) HIV-1 CA assembled into long and hollow tubes in vitro and 
(B) HIV-1 CA assembled into small spheres. The scale bar represents 100nm.  
 









Figure 1.9. Cryo-EM reconstruction of HIV-1 CA tubular assembly. (a) A cryo-EM 
image of CA tubular assembly. Scale bar, 100nm. (b) Electron density map of the CA 
tube with helical symmetry, yellow arrows indicate pairs of helix H9, located between 
adjacent hexamers. (c) Molecular dynamics flexible fitting (MDFF) model of the HIV-1 
capsid assembly, superimposed with the electron density map contoured at 4.0σ, three 
CA hexamers, with NTDs (blue) and CTDs (orange), are shown. (d) MDFF model of a 
CA monomer viewed from two angles. (e) Two CTD dimer structures along -1 (orange) 
and 11 (yellow) helical directions, superimposed onto the NMR solution dimer structure 
(grey, 2KOD). 
 






 Structure of HIV-1 CA domains is highly associated with HIV-1 replication and 
infectivity. In the infectious virions, the mature CA assembles in vitro into three shapes: 
cylinders, cones, and spheres. This variation in shapes resulted from the distribution of 
12 pentameric declinations within the hexameric lattice of CA. The ‘cylindrical’ capsids 
are obtained when tubular capsids are formed by 6 pentamers at each end of tube. An 
asymmetric distribution of the pentamers at the two ends results in ‘conical’ capsids 
while ‘spherical’ capsids arise from an even distribution of the pentamers throughout the 
hexameric lattice (Li et al., 2000; Ganser-Pornillos et al., 2004). It has been reported that 
the HIV-1 infectivity was reduced in the presence of virions with irregular core 
morphologies and heterogenous sizes of CA (Neira, 2009).  
Furthermore, numerous mutagenesis studies have shown that amino acid 
substitutions in capsid protein lead to a reduced HIV-1 infectivity. It has been shown 
that mutation of arginine 18 to leucine at a site where helix-1 from the six NTDs are at 
their closest approach, altered the morphology of the in vitro assembled particles 
(Ganser-Pornillos et al., 2004). Alanine substitutions of tryptophan 184 and methionine 
185 of helix-9 in the CTD diminish the dimerization in vitro and HIV-1 infectivity in 
vivo (Ganser-Pornillos et al., 2007). Furthermore, a single amino-acid deletion in HIV-1 
CA CTD forms a ‘domain-swapped’ dimer in which its function in HIV-1 assembly and 
maturation was disrupted (Ivanov et al., 2007). These evidences suggest that the capsid 
protein is a highly viable target for anti-HIV therapy.  
 
 
